Trial Profile
An Open-label Randomized Parallel Two-arm Multicenter Study of Eribulin Versus Vinorelbine in Female Subjects With Locally Recurrent or Metastatic Breast Cancer, Previously Treated With At Least Two and a Maximum of Five Prior Chemotherapy Regimens, Including an Anthracycline and a Taxane
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Eribulin (Primary) ; Vinorelbine
- Indications Advanced breast cancer; Carcinoma
- Focus Pharmacokinetics; Registrational; Therapeutic Use
- Sponsors Eisai Co Ltd
- 13 Sep 2022 Results of post-hoc analysis of three trials (NCT00388726, NCT00337103 and NCT02225470) assessing efficacy of eribulin mesylate in HER2-low metastatic breast cancer, presented at the 47th European Society for Medical Oncology Congress
- 10 Sep 2022 Results of post-hoc analysis published in the Eisai Inc Media Release.
- 10 Sep 2022 According to an Eisai Inc media release, results from a post-hoc analysis of three trials (NCT00388726, NCT00337103 and NCT02225470) were presented as a poster (Presentation: #259P) at the European Society for Medical Oncology (ESMO) Annual Meeting (#ESMO22).